MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: Risk Capital_Angel, Venture (VC), Strategic Corporate( CVC), Private Equity (PE), Mergers and Acquisition (M&A) (Facts & Figures)
Venture-Geographic Data
*Bioscience Regional Clusters & HotSpots
*Industry: Northern California & Silicon Valley
Structure Therapeutics, Inc. (NASDAQ: GPCR)
Organization & Developments: Structure Therapeutics
Parents
Structure Therapeutics, Inc. (NASDAQ: GPCR)
Children
*Lead candidate is GSBR-1290, a small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.
*Platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs.
*Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology.
2023: Structure Therapeutics And Its Unstructured Weight Loss Data_seekingalpha.com
2024: Structure pill leads to competitive weight loss in obesity study
2024: Structure Therapeutics (GPCR): Innovating Oral Therapies for Obesity and Diabetes
2024: Structure Therapeutics: Pay Attention To This Overlooked Player In GLP-1 Weight Loss Field_ seekingalpha.com
2024: Structure Therapeutics: Potential To Have Best-In-Class GLP-1 Agonist For Obesity Patients
2025: Can Structure Therapeutics' Obesity Drug Challenge Wegovy? Trial Enrollment Complete
2025: Structure Therapeutics: Competitive Data Is Emerging
2025: Structure Therapeutics: Why Aleniglipron's Path To Market Remains Treacherous
2025: Structure: A Lot Riding On Next Data Readout For Oral GLP-1 Candidate
Jumps
Finance & Acquisitions: Structure Therapeutics
Key People: Structure Therapeutics